Epic Medical Research | Red Oak, TX

Research site

(Unclaimed)

Location

106 Plaza Drive, Red Oak, Texas, United States of America

Site insights

Top conditions

Top treatments

Ritonavir

PF-07321332

Orforglipron

LY3298176

AD109

LY3502970

AXA1125

SEL-212

Ianalumab

Guselkumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

14 of 29 total trials

A Study of Baricitinib in Participants With Rheumatoid Arthritis (RA-BRANCH)

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous throm...

Enrolling

Rheumatoid Arthritis

Drug: Baricitinib

Drug: TNF Inhibitor

Locations recently updated

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Enrolling

Chronic Kidney Disease

Overweight

Drug: Orforglipron

Drug: Insulin Glargine

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease (STAR)

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by...

Enrolling

Arthritis, Psoriatic

Drug: Placebo

Drug: Guselkumab

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Enrolling

Primary Prevention of Atherosclerotic Cardiovascular Disease

Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL

Drug: Placebo in 1.5ml

A Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus

The purpose of this study is to evaluate the efficacy of nipocalimab versus placebo in participants with active systemic lupus erythematosus (SLE).

Active, not recruiting

Systemic Lupus Erythematosus

Other: Placebo

Drug: Standard-of-care treatment

A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)

This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult part...

Active, not recruiting

Overweight

Obesity

Drug: Orforglipron

Drug: Placebo

A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19 (SPRINT)

Study of EDP-235 in Non-hospitalized Adults with Mild or Moderate COVID-19.

Enrolling

COVID-19

Drug: Placebo

Drug: EDP-235

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age

The main purpose of this study is to evaluate the efficacy of mRNA 1647 vaccine in CMV-seronegative female participants and to evaluate the safety an...

Active, not recruiting

Cytomegalovirus Infection

Biological: mRNA-1647

Biological: Placebo

Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)

This is a Phase 3 Randomized Double-Blind Placebo-Controlled 6-month Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Ob...

Enrolling

OSA

Drug: Placebo

Drug: AD109

Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneou...

Enrolling

Systemic Lupus Erythematosus

Drug: Placebo

Drug: Ianalumab

Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis

This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving fat and inflammation (stea...

Enrolling

Non Alcoholic Steatohepatitis (NASH)

Drug: AXA1125

Drug: Placebo

Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease (Abroad)

Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Cli...

Active, not recruiting

Alzheimer's Disease (AD)

Drug: Placebo for ABBV-552

Drug: ABBV-552

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age

The purpose of the Phase 1 Part of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1403 and mRNA-1405 in healthy adu...

Active, not recruiting

Norovirus Acute Gastroenteritis

Biological: mRNA-1403

Biological: Placebo

Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Neurostimulation (OSPREY)

Multi-center, open-label, prospective, randomized clinical trial of the aura6000(R) System for the reduction of apnea and hypopneas in adult patients...

Active, not recruiting

Hypopnea, Sleep

Apnea, Obstructive Sleep

Device: Hypoglossal Nerve Stimulation